Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dendritic cell cancer vaccine: Phase I/II

In a U.S. Phase I/II trial in 39 patients, data showed a significant

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE